open access

Vol 13, No 1 (2018)
Heart failure
Published online: 2018-03-22
Get Citation

Patient with heart failure in vulnerable phase

Katarzyna Matyjas, Małgorzata Lelonek
DOI: 10.5603/FC.2018.0014
·
Folia Cardiologica 2018;13(1):71-78.

open access

Vol 13, No 1 (2018)
Heart failure
Published online: 2018-03-22

Abstract

Heart failure is still a serious clinical problem. Each subsequent hospitalization due to acute heart failure worsens
prognosis and increases risk of death in patients with heart failure. Prevention of re-hospitalizations is one of the main
therapeutic goals of heart failure treatment. The most important prognostic period for patient with acute heart failure
and decompensation of chronic heart failure is called vulnerable phase. This is a time from acute symptoms of disease
to six months after discharge from hospital. Vulnerable phase contains three periods: very early phase, early phase
and late phase. Identification of therapeutic goals in each of these phases is pivotal for long-term clinical stabilization.
Optimal pharmacological treatment and complex, multidisciplinary care on each of these phases results in reduction
of re-hospitalizations and improvement of prognosis patients with heart failure.

Abstract

Heart failure is still a serious clinical problem. Each subsequent hospitalization due to acute heart failure worsens
prognosis and increases risk of death in patients with heart failure. Prevention of re-hospitalizations is one of the main
therapeutic goals of heart failure treatment. The most important prognostic period for patient with acute heart failure
and decompensation of chronic heart failure is called vulnerable phase. This is a time from acute symptoms of disease
to six months after discharge from hospital. Vulnerable phase contains three periods: very early phase, early phase
and late phase. Identification of therapeutic goals in each of these phases is pivotal for long-term clinical stabilization.
Optimal pharmacological treatment and complex, multidisciplinary care on each of these phases results in reduction
of re-hospitalizations and improvement of prognosis patients with heart failure.

Get Citation

Keywords

heart failure, vulnerable phase

About this article
Title

Patient with heart failure in vulnerable phase

Journal

Folia Cardiologica

Issue

Vol 13, No 1 (2018)

Pages

71-78

Published online

2018-03-22

DOI

10.5603/FC.2018.0014

Bibliographic record

Folia Cardiologica 2018;13(1):71-78.

Keywords

heart failure
vulnerable phase

Authors

Katarzyna Matyjas
Małgorzata Lelonek

References (34)
  1. Ponikowski P, Voors AA, Anker SD, et al. Authors/Task Force Members, Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016; 18(8): 891–975.
  2. Rywik TM, Kołodziej P, Targoński R, et al. Characteristics of the heart failure population in Poland: ZOPAN, a multicentre national programme. Kardiol Pol. 2011; 69(1): 24–31.
  3. Rywik TM, Zieliński T, Piotrowski W, et al. Heart failure patients from hospital settings in Poland: population characteristics and treatment patterns, a multicenter retrospective study. Cardiol J. 2008; 15(2): 169–180.
  4. Fang J, Mensah GA, Croft JB, et al. Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol. 2008; 52(6): 428–434.
  5. Czech M, Opolski G, Zdrojewski T, et al. Koszty HF w Polsce z punktu widzenia płatnika. Program oceny diagnostyki, leczenia i kosztów u chorych z HF w losowo wybranych jednostkach lecznictwa otwartego i zamkniętego na poziomie podstawowym, wojewódzkim i specjalalistycznym: POLKARD. Kardiologia Polska. 2013; 71(3): 224–232.
  6. Lelonek M. Niewydolność serca i powtarzające się hospitalizacje. Folia Cardiologica. 2016; 11(1): 37–46.
  7. Lloyd-Jones D, Adams RJ, Brown TM, et al. Writing Group Members, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010; 121(7): e46–e4e215.
  8. Cook TD, Greene SJ, Kalogeropoulos AP, et al. Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial). Am J Cardiol. 2016; 117(4): 611–616.
  9. Solomon SD, Dobson J, Pocock S, et al. Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007; 116(13): 1482–1487.
  10. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007; 154(2): 260–266.
  11. Desai AS. The three-phase terrain of heart failure readmissions. Circ Heart Fail. 2012; 5(4): 398–400.
  12. Gheorghiade M, Pang PS, Ambrosy AP, et al. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Fail Rev. 2012; 17(3): 485–509.
  13. Yilmaz MB, Mebazaa A. Definition and characteristics of the vulnerable phase in heart failure. Medicographia. 2015; 37(2): 139–143.
  14. Ponikowski P, Jankowska E. Treatment optimization in heart failure patients from admission to discharge. Medicographia. 2015; 37(2): 149–154.
  15. Teerlink JR, Cotter G, Davison BA, et al. RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013; 381(9860): 29–39.
  16. Butler J, Braunwald E, Gheorghiade M. Recognizing worsening chronic heart failure as an entity and an end point in clinical trials. JAMA. 2014; 312(8): 789–790.
  17. Harjola VP, Mullens W, Banaszewski M, et al. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017; 19(7): 821–836.
  18. Nikolaou M, Parissis J, Yilmaz MB, et al. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J. 2013; 34(10): 742–749.
  19. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the management of heart failure. Journal of the American College of Cardiology. 2013; 62(16): e147–e239.
  20. Bohm M. Changes in predicting heart failure readmission: focus on heart rate. Medicographia. 2015; 37(2): 197–201.
  21. Fonarow GC, Abraham WT, Albert NM, et al. Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). Am J Cardiol. 2008; 102(11): 1524–1529.
  22. DeVore AD, Mi X, Mentz RJ, et al. Discharge heart rate and β-blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry. Am Heart J. 2016; 173: 172–178.
  23. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. The Lancet. 2010; 376(9744): 875–885.
  24. Hidalgo FJ, Anguita M, Castillo JC, et al. Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): A randomised study. Int J Cardiol. 2016; 217: 7–11.
  25. McMurray JJV, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11): 993–1004.
  26. Sobczak S, Lelonek M. LCZ696 przełomem w leczeniu przewlekłej niewydolności serca z obniżoną frakcją wyrzutową lewej komory. Folia Cardiologica. 2016; 10(6): 403–409.
  27. Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003; 42(7): 1226–1233.
  28. van Deursen VM, Urso R, Laroche C, et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail. 2014; 16(1): 103–111.
  29. Cichocka-Radwan A, Lelonek M. Czynniki prognostyczne w obserwacji rocznej w przewlekłej niewydolności serca u chorych po 80. roku życia. Kardiologia Polska. 2017; 75(2): 164–173.
  30. Zile MR, Bennett TD, St John Sutton M, et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 2008; 118(14): 1433–1441.
  31. Cohen Solal A, Leurs I, Assyag P, et al. French National College of Cardiologists. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey. Arch Cardiovasc Dis. 2012; 105(6-7): 355–365.
  32. Metra M, Gheorghiade M, Bonow RO, et al. Postdischarge assessment after a heart failure hospitalization: the next step forward. Circulation. 2010; 122(18): 1782–1785.
  33. McAlister FA, Stewart S, Ferrua S, et al. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol. 2004; 44(4): 810–819.
  34. Feltner C, Jones CD, Cené CW, et al. Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis. Ann Intern Med. 2014; 160(11): 774–784.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl